Program
AD-230
A development code. Also written as “AD-230 (Fasted)”, “AD-230 (Fed)” and “AD-230, AD-2301”.
Its studies are led by Yuhan.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Yuhan | 22 open or running | phase 1since Apr 3, 2026 | Apr 3, 2026 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 3, 2026First study: phase 1 study in Chronic Liver Disease (CLD)First studyNCT07521241 · 52 planned · South Korea
- May 26, 2026Phase 1 study in Chronic Liver Disease (CLD)NCT07618845 · 24 planned · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07618845Chronic Liver Disease (CLD) · South Korea | 1 | Not yet recruiting | Jul 2026 | 24 |
| NCT07521241Chronic Liver Disease (CLD) · South Korea | 1 | Not yet recruiting | Jun 2026 | 52 |
How it is read
Names in the registry
- “AD-230 (Fasted)”, 1 entry
- “AD-230 (Fed)”, 1 entry
- “AD-230, AD-2301”, 1 entry
Codes read as this program: AD230.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.